CINGULATE THERAPEUTICS

Serial Number 87878041
Registration 6144564
700

Registration Progress

Application Filed
Apr 16, 2018
Under Examination
Approved for Publication
Jun 23, 2020
Published for Opposition
Jun 23, 2020
Registered
Sep 8, 2020

Basic Information

Serial Number
87878041
Registration Number
6144564
Filing Date
April 16, 2018
Registration Date
September 8, 2020
Published for Opposition
June 23, 2020
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Sep 8, 2020
Registration
Registered
Classes
042

Rights Holder

Cingulate Therapeutics LLC

16
Address
Suite 310
1901 W 47th Place
Kansas City, KS 66205

Ownership History

Cingulate Therapeutics LLC

Original Applicant
16
Kansas City, KS

Cingulate Therapeutics LLC

Owner at Publication
16
Kansas City, KS

Cingulate Therapeutics LLC

Original Registrant
16
Kansas City, KS

Legal Representation

Attorney
Susan Neuberger Weller

USPTO Deadlines

Next Deadline
426 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-09-08)
Due Date
September 08, 2026
Grace Period Ends
March 08, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

23 events
Date Code Type Description
Jul 20, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 20, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 20, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 8, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER
Jun 23, 2020 PUBO A PUBLISHED FOR OPPOSITION
Jun 23, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 3, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 21, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 12, 2020 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 21, 2019 RCSC S REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 8, 2019 ALIE A ASSIGNED TO LIE
Jan 7, 2019 CNSL R SUSPENSION LETTER WRITTEN
Jan 7, 2019 GNSL S LETTER OF SUSPENSION E-MAILED
Jan 7, 2019 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 14, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 13, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 13, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 13, 2018 CNRT R NON-FINAL ACTION WRITTEN
Aug 13, 2018 GNRT F NON-FINAL ACTION E-MAILED
Aug 13, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 4, 2018 DOCK D ASSIGNED TO EXAMINER
Apr 23, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 19, 2018 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 042
Research and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)
First Use Anywhere: Jun 1, 2014
First Use in Commerce: Jun 1, 2014

Classification

International Classes
042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"THERAPEUTICS"